Avecho’s Phase III Clinical Trial for Insomnia Commences
Avecho has commenced patient recruitment for its pivotal Phase III clinical trial testing its oral cannabidiol TPM®-enhanced soft-gel capsule for insomnia.
The trial is the largest insomnia study of its kind testing cannabidiol, seeking to recruit 519 patients across sites located in Melbourne, Sydney, Central Coast, Brisbane, and Perth. The treatment groups will compare nightly cannabidiol doses of 75 and 150mg cannabidiol with placebo over an 8-week dosing period.
In Australia, as many as 60% of the population have at least some symptoms of insomnia with a total cost to the Australian economy estimated to be $19.1 billion. The global insomnia market is estimated at more than $4 billion.
Avecho CEO, Dr Paul Gavin, said:
“Avecho’s pivotal Phase III clinical trial testing our oral CBD TPM-enhanced soft-gel capsule is the largest and most robust trial of its kind assessing cannabidiol’s effect on insomnia, and will aim to prove, with meticulous trial design and regulatory compliance, a place for CBD in the treatment of insomnia.”
Patients interested in participating are invited to visit the clinical trial recruitment portal at cbdinsomniastudy.com.